Vemurafenib (Zelboraf) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Oct 30, 2026

Some Vemurafenib products are in shortage in Canada (1 of 1 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.

A BRAF inhibitor used to treat melanoma with a specific gene mutation.

Products affected

1 / 1

Reports on file

Talk to a pharmacist

Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.

Book a pharmacist appointment

Need your prescription switched?

If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.

See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Reports by product

Active shortage

ZELBORAF

240MG · TABLET · HOFFMANN-LA ROCHE LIMITED

DIN 02380242 · since ?, no end estimate

What's happening

Vemurafenib is currently affected by an active shortage report filed with Health Canada by HOFFMANN-LA ROCHE LIMITED.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Vemurafenib is classified under “OTHER ANTINEOPLASTIC AGENTS” (ATC L01XE).

Recent changes

Oct 30, 2026 Status changed

Common questions

What is Vemurafenib used for?

A BRAF inhibitor used to treat melanoma with a specific gene mutation.

When will Vemurafenib be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Vemurafenib in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (other antineoplastic agents)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Aminolevulinic Acid (Levulan Kerastick) No current shortage Anagrelide (Agrylin) No current shortage Hydroxyurea (Hydrea) No current shortage Ipilimumab (Yervoy) No current shortage Methyl Aminolevulinate (Metvix) No current shortage Pegaspargase (Oncaspar) No current shortage

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.